Antibodies or inhibitors that block cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), PD-1, programmed cell death 1 ligand 1 (PD-L1), and CD24 show promising therapeutic effects on cancer treatment (39–41). Here, CD274 is linked to cancer.